Key statistics
As of last trade, Apellis Pharmaceuticals Inc (APLS:NSQ) traded at 23.08, 43.32% above the 52 week low of 16.10 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 23.12 |
|---|---|
| High | 23.18 |
| Low | 22.80 |
| Bid | 23.05 |
| Offer | 23.09 |
| Previous close | 22.83 |
| Average volume | 4.89m |
|---|---|
| Shares outstanding | 126.53m |
| Free float | 108.91m |
| P/E (TTM) | 76.88 |
| Market cap | 2.89bn USD |
| EPS (TTM) | 0.297 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 16:22 GMT.
More ▼
- Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
- Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
- Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
- Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
- New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
- Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
More ▼
